PUMA BIOTECHNOLOGY, INC. : Precio Acción Bourse | PBYI | US74587V1070 | MarketScreener
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology falls more than 20%
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology Inc
Puma Biotechnology, Inc. | LinkedIn
Puma Biotech Inc. is looking forward to going to the top - Industry Global News24
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotechnology
La EMA recomienda no aprobar el fármaco de Puma Biotech
